SEC Comment Letter for RedHill Biopharma Ltd. (RDHL) (CIK 0001553846) (RDHL) — Sep 13, 2016

RedHill Biopharma Ltd. (RDHL) (CIK 0001553846)
Date: Sept. 13, 2016 · CIK: 0001553846 · Accession: 0000000000-16-092641

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-35773

Date

September 12, 2016

Author

/s/ Erin K. Jaskot, for

Form

UPLOAD

Company

RedHill Biopharma Ltd. (RDHL) (CIK 0001553846)

Letter

Mailstop 4546 September 12, 2016 Ori Shilo Deputy Chief Executive Officer Finance and Operations RedHill Biopharma Ltd. 21 Ha’arba’a Street Tel Aviv 64739, Israel

Re: RedHill Biopharma Ltd. Form 20-F Filed February 25, 2016 File No. 001-35773

Dear Mr. Shilo :

We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Erin K. Jaskot, for

Show Raw Text

Mailstop 4546
September 12, 2016

Ori Shilo
Deputy Chief Executive Officer Finance and Operations
RedHill Biopharma Ltd.
21 Ha’arba’a Street
Tel Aviv 64739, Israel

Re: RedHill  Biopharma Ltd.
 Form 20-F
Filed February 25, 2016
File No. 001-35773

Dear Mr. Shilo :

We have completed our review of your filing .  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Erin K. Jaskot, for

 Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

cc: Rick A. Werner, Esq.
 Haynes and Boone, LLP

SecProbe.io